With Intelligence Announces That Motive Partners Has Acquired a Majority Stake
20.7.2023 10:30:00 EEST | Business Wire | Press release
With Intelligence, a leading provider of investment data and intelligence for allocating, fund-raising and business development in the public and private markets, announced that it has received a majority investment from funds advised by Motive Partners (“Motive”), a specialist private equity firm focused on financial technology. Intermediate Capital Group ("ICG"), who originally invested in With Intelligence in 2020, will invest further alongside Motive. The investment is intended to serve as an accelerant for With Intelligence's growth, as the platform focuses on delivering leading connectivity, data and insights solutions to the Limited Partner and General Partner communities.
Founded in 1998, With Intelligence is a leading provider of data, intelligence and connectivity to the global asset management industry, with an integrated product suite of data, insights and events covering hedge funds, private credit, private equity, real estate and traditional asset management. Established 25 years ago, with over 500 employees and a geographic footprint across Europe, North America and Asia, With Intelligence has seen significant growth in recent years, with over 2,500 customers and a revenue compound annual growth rate of 33%.
With Intelligence blends data from a variety of the platform’s proprietary brands, delivering insights that include profiles, fund information, performance metrics and analyst perspectives. As the alternative investment landscape continues to evolve, With Intelligence is positioned to provide solutions that support mission-critical decision making across the fundraising and allocation lifecycle, for all participants in the value-chain. With Intelligence's strong growth is bolstered by a leading position in the hedge fund market, and is beginning to benefit from significant tailwinds driving the growth of private markets towards an estimated $15 trillion of assets under management in 2027.
Charlie Kerr, Founder & CEO at With Intelligence commented: “There is a huge opportunity for us to serve the global asset management industry during an exciting period of growth with greater data and analytics solutions than presently exist in the market. In order to capitalise on these tailwinds, we have chosen to partner with Motive Partners, who have a strong depth of expertise in financial technology across their group of Investors, Operators and Innovators. I am also grateful to ICG for their continued support and investment in the next phase of our growth journey.”
Neil Cochrane, Partner at Motive Partners commented: “We are positioned at the intersection of two exciting trends - the increase of allocations towards alternatives and the emergence of exciting new analytics and AI technologies to derive insights within the sector. Through the Motive IOI model and our extensive network, we are looking forward to capitalising on this market opportunity in partnership with Charlie, the With Intelligence team, and ICG.”
The investment by Motive and ICG will support With Intelligence to accelerate its data strategy and technology capabilities, continue to develop tailored offerings across various asset classes, grow the private markets offerings, and execute the next phase of the partnership and M&A strategies. It will also enable the company to further accelerate the pace of talent acquisition. Additionally, Motive's integrated operating model ("IOI model"), combining Investors, Operators and Innovators, will see a number of Motive team members collaborate with the With Intelligence team, including Charles Teschner (Industry Partner at Motive and the former CEO of Data and Analytics Solutions at BNY Mellon), Andy Stewart (Industry Partner at Motive, current CEO of Wilshire, and the former Co-Head of Blackrock's Alternative Investment Platform) and a team from Motive's innovation division, Motive Create.
“It has been a privilege to support the With Intelligence management team on their outstanding journey over the past few years, working alongside a visionary and entrepreneurial founder such as Charlie" said Jamie Rivers, Managing Director at ICG. Gareth Knight, Head of European Mid-Market at ICG added: "The company has a proven strategy for growth, and we're delighted to support the business for a further Investment cycle. We see Motive Partners being extremely well placed to help accelerate this over the coming years.”
Global investment banking firm Houlihan Lokey served as financial advisor to With Intelligence on the transaction, with other advisors including Proskauer (Legal), Financial & Tax (Alvarez & Marsal) and OC&C (Commercial). Arrowpoint Advisory, Joelson and Blick Rothenberg supported Management. Motive Partners' financial advisor was Raymond James, and they were also advised by MDW Capital Advisory (Debt Advisor), White & Case (Legal), Plural Strategy, Oliver Wyman (Commercial), and EY (Financial & Tax).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230720513739/en/
Contact information
With Intelligence
Louise Green, Chief Marketing Officer
louise.green@withintelligence.com
Motive Partners
Sam Tidswell-Norrish, Managing Director
sam@motivepartners.com
ICG
Clare Glynn, Head of Corporate Communications
clare.glynn@icgam.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom